Sinemet, Stalevo(carbidopa)
Carbidopa, Carbidopa / / Levodopa, Carbidopa / Levodopa, Corbilta, Crexont, Dhivy, Duopa, Levodopa/Carbidopa/Entacapone, Lodosyn, Numient, Rytary, Sinemet, Stalevo (carbidopa) is a small molecule pharmaceutical. Carbidopa was first approved as Lodosyn on 1982-01-01. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against aromatic-L-amino-acid decarboxylase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Carbidopa, Lodosyn (discontinued: Carbidopa)
CombinationsCarbidopa levodopa, Carbidopa, levodopa entacapone, Crexont, Dhivy, Duopa, Rytary, Sinemet, Stalevo (discontinued: Carbidopa levodopa, Carbidopa, levodopa entacapone, Carbilev, Parcopa, Sinemet)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carbidopa
+
Levodopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUOPA | AbbVie | N-203952 RX | 2015-01-09 | 1 products, RLD, RS |
| DHIVY | Avion Pharmaceuticals | N-214869 RX | 2021-11-12 | 1 products, RLD, RS |
| RYTARY | Impax Laboratories | N-203312 RX | 2015-01-07 | 4 products, RLD, RS |
| CREXONT | Impax Laboratories | N-217186 RX | 2024-08-07 | 4 products, RLD, RS |
| SINEMET | Organon | N-017555 RX | 1982-01-01 | 3 products, RLD |
Show 1 discontinued
Carbidopa
+
Entacapone
+
Levodopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| STALEVO 50 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD, RS |
| STALEVO 100 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
| STALEVO 150 | Orion Pharma | N-021485 RX | 2003-06-11 | 1 products, RLD |
| STALEVO 200 | Orion Pharma | N-021485 RX | 2007-08-02 | 1 products, RLD, RS |
| STALEVO 75 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
| STALEVO 125 | Orion Pharma | N-021485 RX | 2008-08-29 | 1 products, RLD |
Carbidopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LODOSYN | Aton Pharma | N-017830 RX | 1982-01-01 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carbidopa | ANDA | 2024-07-27 |
| carbidopa and levodopa | ANDA | 2024-11-04 |
| carbidopa tablets, 25 mg | ANDA | 2023-11-14 |
| carbidopa, levodopa and entacapone | ANDA | 2022-02-01 |
| carbidopa, levodopa, and entacapone | NDA authorized generic | 2016-02-01 |
| carbidopa-levodopa | ANDA | 2023-04-08 |
| crexont | New Drug Application | 2024-08-07 |
| dhivy | New Drug Application | 2024-01-31 |
| duopa | New Drug Application | 2022-03-04 |
| lodosyn | New Drug Application | 2020-07-01 |
Show 4 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Carbidopa / Levodopa, Dhivy, Avion Pharms | |||
| 11033521 | 2039-03-28 | DP | U-219, U-3304, U-3305 |
| 11439613 | 2039-03-28 | U-3557 | |
| 11819485 | 2039-03-28 | U-3557 | |
| Carbidopa / Levodopa, Rytary, Impax Labs Inc | |||
| 8377474 | 2028-12-26 | DP | U-219, U-1645 |
| 8454998 | 2028-12-26 | DP | U-219, U-1645, U-1646, U-1647, U-1649 |
| 8557283 | 2028-12-26 | DP | U-219, U-1645 |
| 9089607 | 2028-12-26 | DP | U-1645, U-1720 |
| 9089608 | 2028-12-26 | DP | |
| 9463246 | 2028-12-26 | DP | U-219 |
| 9533046 | 2028-12-26 | DP | U-219 |
| 9901640 | 2028-12-26 | DP | U-219 |
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J7340 | Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml |
Clinical
Clinical Trials
269 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 45 | 50 | 40 | 23 | 29 | 178 |
| Depression | D003863 | — | F33.9 | — | 1 | — | 5 | 2 | 8 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | — | 5 | 1 | 8 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 2 | 2 | 2 | 2 | 7 |
| Dyskinesias | D020820 | HP_0002310 | G24 | 1 | 1 | 2 | 1 | 1 | 6 |
| Back pain | D001416 | HP_0003418 | M54 | — | 2 | — | 1 | — | 3 |
| Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | — | 1 | — | 1 | 1 | 3 |
| Anhedonia | D059445 | — | R45.84 | — | 1 | — | 2 | — | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | 1 | 1 | 3 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 1 | — | 1 | — | 2 |
Show 13 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | 6 | 1 | — | — | 7 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 3 | 3 | 2 | — | — | 5 |
| Syndrome | D013577 | — | — | 1 | 2 | 2 | — | 1 | 4 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 1 | 2 | 1 | — | — | 3 |
| Primary dysautonomias | D054969 | — | — | 1 | 2 | 1 | — | — | 3 |
| Angelman syndrome | D017204 | Orphanet_72 | Q93.51 | 1 | 1 | 1 | — | 1 | 3 |
| Disease | D004194 | EFO_0000408 | R69 | 1 | — | 1 | — | — | 2 |
| Familial dysautonomia | D004402 | Orphanet_1764 | G90.1 | — | 1 | 1 | — | — | 2 |
| Amblyopia | D000550 | HP_0000646 | H53.00 | — | 1 | 1 | — | — | 2 |
| Stroke rehabilitation | D000071939 | — | — | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 5 | — | — | — | 5 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | 3 | — | — | 1 | 4 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | 2 | 1 | — | — | 1 | 3 |
| Multiple system atrophy | D019578 | — | — | 2 | 1 | — | — | 1 | 3 |
| Sclerosis | D012598 | — | — | 2 | 1 | — | — | — | 3 |
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 2 | — | — | — | 2 |
| Brain diseases | D001927 | HP_0001298 | G93.40 | — | 2 | — | — | — | 2 |
| Movement disorders | D009069 | HP_0100022 | — | — | 2 | — | — | — | 2 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | — | — | — | 2 |
| Brain injuries | D001930 | — | S06.9 | 2 | 1 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Pure autonomic failure | D054970 | — | — | 3 | — | — | — | — | 3 |
| Parkinsonian disorders | D020734 | HP_0001300 | G20.C | 1 | — | — | — | 2 | 3 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 2 | — | — | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | 1 | — | — | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Show 12 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Huntington disease | D006816 | Orphanet_399 | G10 | — | — | — | — | 1 | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
| Corticobasal degeneration | D000088282 | — | — | — | — | — | — | 1 | 1 |
| Narcolepsy | D009290 | HP_0030050 | G47.4 | — | — | — | — | 1 | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 1 | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | — | — | 1 | 1 |
| Sleepiness | D000077260 | — | R40.0 | — | — | — | — | 1 | 1 |
| Memory consolidation | D000069077 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Carbidopa |
| INN | carbidopa |
| Description | Carbidopa (anhydrous) is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug and a dopaminergic agent. It is a member of hydrazines, a monocarboxylic acid and a member of catechols. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O |
Identifiers
| PDB | — |
| CAS-ID | 38821-49-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200748 |
| ChEBI ID | 3395 |
| PubChem CID | 34359 |
| DrugBank | DB00190 |
| UNII ID | KR87B45RGH (ChemIDplus, GSRS) |
Target
Agency Approved
DDC
DDC
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Duopa – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Rytary – Amneal Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Sinemet – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Carbidopa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Carbidopa
+
Entacapone
+
Levodopa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Carbidopa
+
Levodopa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,100 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
53,080 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use